GENEVA, Feb. 9, 2011 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company specializing in the rapid development and engineering of high yield and stable mammalian cell-lines for therapeutic protein manufacturing, announced today a major expansion of the company’s Swiss-based laboratories and staff. The additional space comes in response to the increasing global demand for recombinant therapeutic proteins as well as outsourcing support for the rapid production of recombinant proteins.
Selexis’ Swiss-based facilities now total over 13,000 square feet, a 100% increase over the former space. This is the second major expansion for the company that originally opened in 2001 as a spin-off from the University of Lausanne. The additional space houses larger laboratory and production functions, including a protein purification unit for small batches of purified research/pre-clinical proteins. The Company will also increase the R&D and sales staff by more than 30%. The additional facilities and staff will enable Selexis to effectively service current and future client demands, while providing needed capacity to further expand its leading Selexis SURE Technology Platform and services.
“Our expansion was prompted by the global demand for outsourcing cell line engineering, the manufacturing of recombinant protein for pre-clinical research and interest in biosimilars as well as emerging technologies such as protein scaffolds. This investment will enable Selexis to provide even greater value to our current and future customers,” said Dr. Igor Fisch, CEO, Selexis SA. “Our new laboratory space and staff represents a significant expansion for our business.”
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company’s SURE Cell Line Development Technology Platform is based on Selexis Genetic Elements -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors, Selexis SUREfection Transfection Methods, Selexis VS Variant Screening and the proprietary Selexis CHO-M cell line.
For more information, visit http://www.selexis.com
Media Contact: | |
Robert Meister, Head of Marketing Communications | |
Selexis SA | |
+1-602-953-1716 | |
SOURCE Selexis SA
